Aim To compare the risks of cardiovascular disease (CVD) and all-cause mortality associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP4i) and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy in people with Type 2 diabetes.
Introduction
Type 2 diabetes, which accounts for most people with diabetes, is an important risk factor for cardiovascular disease (CVD), peripheral vascular disease and metabolic conditions, all of which increase the risk of mortality [1] [2] [3] . For people with Type 2 diabetes, effective glycaemic control with appropriate glucose-lowering drugs, as well as lifestyle modifications, are needed to minimize the risk of complications. Metformin (MET) is the standard first-line drug for Type 2 diabetes and has established benefits against cardiovascular risk [4] . However, if MET therapy fails to maintain the target glucose level, a second-line agent is often administered as an add-on therapy. However, the selection of an ideal second-line therapy remains controversial because of personal preferences, costs and, most importantly, efficacy and safety issues.
Many previous clinical trials and observational studies have investigated the cardiovascular risks associated with second-line agents as add-ons to MET and have reported various conclusions. Most large trials designed to evaluate the effects of various diabetes drugs on intensive glycaemic control have investigated the comparative effects of these drugs on CVD, but are not representative of life in the real world. Several observational studies are limited by a small sample size or differing baseline characteristics between treatment groups. Moreover, although the efficacy of diabetes drugs might differ among ethnic groups, only a few studies have investigated the cardiovascular effects of secondline drugs in Asian populations. We therefore conducted a real-world cohort study to compare the cardiovascular risks of second-line anti-diabetes medications among people with 
Methods

Study participants and exposure data
In Korea, the National Health Insurance Service (NHIS), a compulsory single-payer national healthcare coverage system, has covered the entire population of South Korea since 1989. The NHIS claims database includes an anonymized research dataset of demographic information, diagnoses, prescriptions, referrals and vital status information. Diagnoses are coded using the International Classification of Diseases, 10th revision (ICD-10). The NHIS requires all insured employees and self-employed persons aged ≥ 40 years, and their dependents to undergo general health screenings every 2 years. The resulting NHIS health screening dataset includes body size, brachial blood pressure, fasting blood chemistry data, health behaviours, and personal and family histories of disease. In this study, the primary analysis used only the claims dataset, and the secondary analysis used both the claim and health screening datasets.
The study protocol was reviewed and approved by the Institutional Review Board of Severance Hospital at Yonsei University College of Medicine (IRB No. 4-2015-1023) .
The main exposure in this study was the use of diabetes drugs as an add-on medication to MET. From the NHIS claims database, we extracted prescription information for diabetes drugs given to 2 562 020 people with Type 2 diabetes (ICD-10 code, E11 to E14) between January 2011 and December 2012. To increase comparability within the study population, people who used MET monotherapy for at least 90 days were included, but those who used other treatment regimens (including combinations with metformin) were excluded. By applying these criteria, 256 987 persons remained. Second-line diabetes regimens were limited to the most common three drugs: sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP4i) and thiazolidinedione (TZD). The initiation date of the above regimen was defined as the index date. We also excluded:
1. people aged < 30 or > 90 years at the index date, 2. those with a CVD or cancer diagnosis ≤ 90 days since the index date, 3 . those who received insulin therapy or second-line therapy other than the study regimens ( Fig. 1 ).
This left 40 263 individuals available for statistical analysis. The follow-up time was defined as the period between the index date and the earliest of:
1. the date of the first outcome event 2. the date of death from any cause 3. the end of the study period (30 June 2015) .
Outcomes
Study outcomes were CVD events and all-cause mortality. CVD was defined as hospitalisation or an emergency department visit for coronary heart disease (myocardial infarction, unstable angina or coronary revascularisation), heart failure, stroke or transient cerebral ischaemic attack, but not peripheral vascular disease. We used the earliest recorded date of any of these events as the date of CVD onset. All-cause mortality was defined by the death status in the NHIS database, which was linked to the National Death Registry using unique resident registration numbers.
Covariates
To minimize confounding effects, covariates, including age, sex, calendar index year, MET monotherapy duration and comorbidities, were subjected to serial statistical adjustments. Comorbidities were adjusted using the Charlson comorbidity score [5] , as well as individual conditions such as hypertension, dyslipidaemia, atrial fibrillation, chronic kidney disease, rheumatoid arthritis and microvascular complications of diabetes. A secondary subgroup analysis included additional covariates such as BMI, waist circumference, systolic blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, fasting glucose, serum creatinine, smoking status (non-smoker; former smoker; current smoker), and family history of stroke and heart disease; these had been measured via health screening within 1 year prior to the index date. A list of outcomes and confounder variables with corresponding ICD-10 codes, procedure codes, or Anatomical Therapeutic Chemical is available in Table S1 .
Statistical analyses
Baseline characteristics were compared between different second-line drugs. The times from second-line regimen initiation to outcome events were analyzed using KaplanMeier graphs, and survival curves were compared using the What's new?
• Nationwide real-world data from Korea was used to compare cardiovascular disease and all-cause mortality associated with add-on medications to metformin therapy.
• Compared with sulfonylurea add-on to metformin, a dipeptidyl peptidase-4 inhibitor add-on to metformin might correlate with lower risk of cardiovascular disease events and all-cause mortality.
log-rank test. Cox proportional hazards regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD incidence and all-cause mortality for comparator second-line regimens versus the referent second-line regimen (MET + SU). Potential confounders were sequentially adjusted in three statistical ª 2017 Diabetes UK models as follows: model 1, age and sex; model 2, age, sex, duration of MET therapy and comorbidities (hypertension, dyslipidaemia, atrial fibrillation, chronic kidney disease, rheumatoid arthritis and microvascular complications of diabetes); model 3, model 2 plus calendar index year and Charlson comorbidity score. A secondary analysis of health screening data also comprised three models: model 1, adjusted for age and sex; model 2, adjusted for age, sex, duration of MET therapy, BMI, waist circumference, systolic blood pressure, total cholesterol, HDL-cholesterol, LDLcholesterol, triglycerides, fasting glucose, serum creatinine level, smoking status, and family history of stroke and heart disease; model 3, model 2 plus calendar index year and Charlson comorbidity score. As a sensitivity analysis, the three regimen groups were balanced with propensity matching in a 1 : 1 : 1 ratio, then the matched subgroups were compared for outcomes. All analyses were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Among the 40 263 people who used second-line drugs with MET, those using SU, DPP4i and TZD accounted for 28.8% (n = 11 582), 66.1% (n = 26 623) and 5.1% (n = 2058), respectively. The mean index age of the study population was 60.0 years, and 54.3% were male. After an average of 2.3 years of MET monotherapy, second-line regimens were added. Compared with those who added SU, the persons who added DPP4i or TZD to MET therapy were younger, had been received MET monotherapy for a relatively longer duration, and had a lower prevalence of hypertension and higher prevalence of dyslipidaemia. Persons who used DPP4i as a second-line drug were more likely to have used antiplatelet drugs than those who used other second-line drugs (Table 1) . A total of 1289 cases of CVD and 289 cases of death were observed during the 62 166 person-years comprising the follow-up period. People treated with MET + SU had a relatively higher CVD incidence and all-cause mortality rate, compared with those treated with MET + DPP4i or MET + TZD (Fig. 2) .
The sex and age-adjusted HR of CVD was 0.78 (P ≤ 0.001) for MET + DPP4i therapy, compared with MET + SU therapy. This lower CVD risk remained significant after additional adjustments for comorbidities, MET monotherapy duration and the calendar year of second-line medication initiation. MET + TZD therapy was associated with a lower CVD risk, compared with MET + SU therapy (sex and age-adjusted HR 0.82; P = 0.156), although the association was not statistically significant possibly due to small sample size. Only 60 CVD events were observed among the 3014 people who received prescriptions for MET + TZD (Table 2) . We repeated this analysis for subgroups categorized by sex, age and hypertension diagnosis. Lowered CVD risk of MET + DPP4i and MET + TZD users, in comparison with MET + SU users, were more prominent in the ≥ 65 years subgroup than in the < 65 years subgroup (P for interaction < 0.001). However, sex and diagnosis of hypertension did not modify the association (Fig. 3) . Mortality rates were also lower in people receiving MET + DPP4i and MET + TZD, compared with MET + SU therapy. However, the differences in all-cause mortality did not reach statistical significance (Table 2) . Because our main analysis excluded people who used MET or second-line drugs for < 90 days, we did a further analysis with 30-and 60-day run-in periods, as well as without a run-in period. Although, there were slight differences in magnitude and significant of association, different run-in period did not severely affect the relationship (Table S2 ). The NHIS claim database included major risk factor variables, but lacked many other CVD risk factors. Therefore, we performed a subgroup analysis with additional adjustment for risk variables which had been measured at health screening examination (Table 3) . Baseline characteristics of the subgroup are summarized in Table S3 , according to the type of second-line drug used. As in the primary analysis, people treated with MET + DPP4i and MET + TZD had a lower CVD in the secondary analysis, compared with those treated with MET + SU therapy, although the relationship did not reach statistical significance, probably due to the smaller sample size. The subgroup analysis for all-cause mortality differed somewhat from those of the primary analysis with entire dataset. Fully adjusted HR for MET + DPP4i (0.44; P = 0.018) was lower than the corresponding ratio in the primary analysis (0.84; P = 0.156).
In order to increase the comparability of clinical characteristics among the three regimen groups, a sensitivity analysis was performed for a subgroup 1 : 1 : 1 matched FIGURE 2 Cumulative incidence of cardiovascular events and all-cause mortality. CVD, cardiovascular disease; Met, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione. with propensity score. The estimated HRs were similar to those of primary analysis, but were not statistically significant because propensity score matching greatly reduced the number of available data: fully adjusted HRs for CVD events were 0.74 (95% CI 0.45-1.22) for MET + DPP4i and 0.92 (95% CI 0.57-1.47) for MET + TZD. We also repeated the analysis using the additive hazard model, which is a flexible semi-parametric model for survival outcomes [6] . The results of the additional model were similar to the main results shown in Tables 2 and 3 (data not shown).
FIGURE 3
Subgroup analysis by sex, age and diagnosis of hypertension. Hazard ratios and 95% confidence intervals for cardiovascular events are shown for comparator second-line regimens vs. the referent second-line regimen (metformin + sulfonylurea). These analyses were adjusted to address potential confounding by age, sex, duration of MET therapy, comorbidities (hypertension, dyslipidaemia, atrial fibrillation, chronic kidney disease, rheumatoid arthritis, and microvascular complications of diabetes), calendar index year and Charlson comorbidity score. Met, metformin; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; AHR, adjusted hazard ratio; CI, confidence interval. 
Discussion
In this analysis of nationwide real-world data, we observed that people with Type 2 diabetes who added a DPP4i as a second-line drug to MET had relatively lower risks of CVD and all-cause mortality, compared with those who added SU. People who added TZD also tended to have lower risks, although these findings did not reach statistical significance.
Our findings are in line with recent retrospective studies that evaluated the CVD risks associated with second-line diabetes drugs added after MET monotherapy [7] [8] [9] [10] [11] . In a study of UK primary care data of 10 118 people, MET + TZD therapy was associated with a 32% lower risk of major cardiovascular events, compared with MET + SU therapy. However, in that study, MET + DPP4i therapy yielded a 22% lower but statistically non-significant risk, compared with MET + SU therapy [11] . Another UK analysis of primary care data revealed that MET + DPP4i was associated with a significant 38% lower risk of major cardiovascular events, compared with MET + SU therapy [10] . Furthermore, in an analysis of Swedish national registries, MET + SU therapy was associated with a significantly higher CVD risk, compared with MET + DPP4i and MET + TZD therapies [8, 9] . Unlike our study and others, however, a study of the Taiwan National Health Insurance database did not find differences in CVD risks among various second-line anti-diabetes agents (SU, DPP4i, glinides, pioglitazone and a-glucosidase inhibitors) added to MET [7] .
A previous Korean analysis of the Health Insurance Review & Assessment Service (HIRA) database reported that treatment with MET + SU was associated with a higher CVD risk, compared with MET + DPP4i treatment. The same analysis also reported an even lower CVD risk with MET + TZD therapy compared MET + DPP4i treatment [12] . These results agree only partially with our findings. We note a few differences between our NHIS database analysis and the earlier HIRA database analysis. First, we limited our analysis to those who added only one drug to MET therapy to maximize the comparability between the second-line drug types. Second, we excluded persons who did not use MET monotherapy prior to combination therapy or who used MET monotherapy for < 90 days. Third, we adjusted for the duration of MET monotherapy as a potential confounder. Finally, we confirmed our primary analysis through a subgroup analysis after adjusting for cardiovascular risk factor levels measured during previous health screenings, whereas health screening data were unavailable in the HIRA database. However, these restrictions and adjustments might have reduced our study sample size to a level that precluded further analyses for specific types of CVD, such as myocardial infarction, heart failure or stroke.
A few randomized clinical trials have directly compared the CVD preventive effects of second-line anti-diabetes medications. Although trials have provided indirect evidence of the effects of these agents, the conflicting findings have made agreement impossible. In a meta-analysis of randomized clinical trials, SU use was associated with increased risks of mortality and stroke, but did not affect the risk of overall CVD relative to other anti-diabetes medications [13] . The meta-analysis also suggested that DPP4i treatment might be associated with a lower CVD risk, compared with SU treatment, although this needs to be confirmed by long-term studies. In people with Type 2 diabetes and a high risk of CVD, treatment with DPP4i was not found to significantly affect the risk of CVD [14] [15] [16] , and although one clinical trial reported an increased risk of heart failure [15] , this result was contradicted by another study [14] . There is increasing evidence that in people with Type 2 diabetes at high risk of CVD, TZD therapy might reduce the risk of CVD but increase that of heart failure [17, 18] .
DPP-4 inhibition may confer vascular protective effects through increased expression of glucagon-like peptide-1, which stimulates insulin, and inhibits glucagon secretion, while exerting off-target effects. These include protecting endothelial cells from hyperglycaemia, immunomodulation, ischaemic injury recovery via stromal derived factor-1a upregulation, and angiogenesis via modulation of neuropeptide Y signalling and renal haemodynamic modulation [19] . DPP4i treatment is known to carry lower risks of hypoglycaemia and weight gain, both of which may contribute to CVD development [20] [21] [22] . In addition, a meta-analysis suggests that DPP4i might more effectively lower glucose levels in Asians vs. other ethnic groups because of differences in BMI distribution [23] .
Glitazones or TZDs selectively stimulate the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-c) and may lower CVD risks by reducing the release of free fatty acids and adipocytokines such as tumour necrosis factor-a, leptin, and resistin, and enhancing the formation of adiponectin [24] . However, studies have reported adverse side effects of TZD such as weight gain caused by PPAR-c activation in adipose tissue and the central nervous system, dilated cardiomyopathy with increased lipid and glycogen stores, and disrupted mitochondria [25] . SU treatment not only yields cardiovascular benefits by decreasing hyperglycaemia, but also causes adverse effects such as hypoglycaemia, weight gain, hypertension and myocardial ischaemic preconditioning mediated through the closure of the cardioprotective K ATP channels in myocytes [13, [26] [27] [28] [29] .
This study had some limitations, which we have tried to address. First, outcome events were ascertained from health insurance claims data, and diagnoses were not adjudicated by medical records or laboratory tests. The accuracy of diagnoses in claim databases is debatable. Recent Korean studies that compared diagnoses from claim databases with medical records observed overall accuracy rates of 72.3% for diabetes, 71.4% for myocardial infarction and 83.4% for ischaemic stroke [30] [31] [32] . There was a possibility of nondifferential misclassification which would bias the risk ratio ª 2017 Diabetes UK toward the null. Second, the study had a relatively short follow-up length. Further studies are needed to compare the long-term effects of second-line anti-diabetes drugs. Third, we could not identify CVD events if patients did not use medical services, even though the NHI system provides health coverage to all Korean residents. In addition, we could not follow-up those who lost their insurance benefits. However, at the end of the follow-up period, only 70 (0.17%) people lost their health insurance qualifications, and the most common cause of disqualification was foreign emigration. In order to determine whether the differential medical service use or follow-up loss caused bias in the study results, we performed as-treated analysis only for those who were continuing to receive diabetes treatment. We have confirmed that the results of as-treated analysis are similar to those of main analysis (Table S4) . Finally, there is a possibility of residual confounding by unmeasured or uncontrolled confounders, because this is an observational study which collected exposure information from health insurance database. However, we observed similar findings in a subgroup analysis where health screening data were available, and from a sensitivity analysis with propensity score matching. There were also differences in baseline characteristics among the three comparison groups. In particular, people using DPP4i tended to use antiplatelet agents more often than those who used other secondary drugs. Therefore, we did a further analysis with additional adjustment for the use of antiplatelet agents, but the findings were same to the results of primary analysis. Therefore, the differences in the CVD and mortality risks between secondline diabetes drugs are not likely to be seriously distorted by confounding factors.
Conclusion
People with Type 2 diabetes often require treatment with multiple anti-diabetes agents to achieve adequate glycaemic control, and safety and CVD prevention efficacy are the most important factors when selecting second-line agents. This analysis of nationwide real-world data from Korea suggested that compared with a SU add-on, a DPP4i add-on to MET might correlate with lower risks of CVD events and all-cause mortality. Larger studies are needed to evaluate the effects of TZD as an add-on to MET. 
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